WO2020141201A1 - Antibacterial oral compositions - Google Patents
Antibacterial oral compositions Download PDFInfo
- Publication number
- WO2020141201A1 WO2020141201A1 PCT/EP2020/050044 EP2020050044W WO2020141201A1 WO 2020141201 A1 WO2020141201 A1 WO 2020141201A1 EP 2020050044 W EP2020050044 W EP 2020050044W WO 2020141201 A1 WO2020141201 A1 WO 2020141201A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oral care
- care composition
- galactooligosaccharide
- xylitol
- liquid oral
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 114
- 230000000844 anti-bacterial Effects 0.000 title description 3
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 67
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 67
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 34
- 229960002675 Xylitol Drugs 0.000 claims abstract description 34
- 239000000811 xylitol Substances 0.000 claims abstract description 34
- 235000010447 xylitol Nutrition 0.000 claims abstract description 34
- 239000007788 liquid Substances 0.000 claims abstract description 27
- 230000000069 prophylaxis Effects 0.000 claims abstract description 17
- 206010065233 Oral bacterial infection Diseases 0.000 claims abstract description 16
- 208000002925 Dental Caries Diseases 0.000 claims description 23
- 206010006326 Breath odour Diseases 0.000 claims description 20
- 239000002324 mouth wash Substances 0.000 claims description 20
- 241000194019 Streptococcus mutans Species 0.000 claims description 16
- 229940031008 Streptococcus mutans Drugs 0.000 claims description 16
- 229940051866 Mouthwash Drugs 0.000 claims description 14
- 210000000214 Mouth Anatomy 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 12
- 239000007921 spray Substances 0.000 claims description 6
- 230000000699 topical Effects 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 2
- 210000004195 Gingiva Anatomy 0.000 claims 1
- 241000605894 Porphyromonas Species 0.000 claims 1
- 230000001603 reducing Effects 0.000 description 15
- 241000605862 Porphyromonas gingivalis Species 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000006722 reduction reaction Methods 0.000 description 9
- 241000605986 Fusobacterium nucleatum Species 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 7
- 229960003082 Galactose Drugs 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 239000003906 humectant Substances 0.000 description 6
- 230000000873 masking Effects 0.000 description 6
- 230000001717 pathogenic Effects 0.000 description 6
- 244000052769 pathogens Species 0.000 description 6
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 6
- 150000003464 sulfur compounds Chemical class 0.000 description 6
- -1 D-galactosyl group Chemical group 0.000 description 5
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 5
- 210000000515 Tooth Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 229920001542 oligosaccharide Polymers 0.000 description 5
- 150000002482 oligosaccharides Polymers 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 210000003298 Dental Enamel Anatomy 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 208000005888 Periodontal Pocket Diseases 0.000 description 4
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 4
- 230000001580 bacterial Effects 0.000 description 4
- 239000006172 buffering agent Substances 0.000 description 4
- 230000001013 cariogenic Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001332 colony forming Effects 0.000 description 4
- 150000004673 fluoride salts Chemical class 0.000 description 4
- LSDPWZHWYPCBBB-UHFFFAOYSA-N methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 4
- 230000003239 periodontal Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000001974 tryptic soy broth Substances 0.000 description 4
- 108010050327 trypticase-soy broth Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 229960001031 Glucose Drugs 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000240 adjuvant Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 230000032770 biofilm formation Effects 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- WBZFUFAFFUEMEI-UHFFFAOYSA-M potassium;6-methyl-2,2-dioxooxathiazin-4-olate Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 3
- 239000011775 sodium fluoride Substances 0.000 description 3
- 235000013024 sodium fluoride Nutrition 0.000 description 3
- 239000012049 topical pharmaceutical composition Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- 238000009631 Broth culture Methods 0.000 description 2
- 229960003260 Chlorhexidine Drugs 0.000 description 2
- 229960001884 Chlorhexidine diacetate Drugs 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N D-galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- 210000000981 Epithelium Anatomy 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Exidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- 229940025294 Hemin Drugs 0.000 description 2
- BTIJJDXEELBZFS-QDUVMHSLSA-K Hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M Potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229940046010 Vitamin K Drugs 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- 229940019697 Vitamin K containing hemostatics Drugs 0.000 description 2
- DJWUNCQRNNEAKC-UHFFFAOYSA-L Zinc acetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O DJWUNCQRNNEAKC-UHFFFAOYSA-L 0.000 description 2
- WDRFFJWBUDTUCA-UHFFFAOYSA-N [amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]-[6-[amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]azaniumylhexyl]azanium;diacetate Chemical compound CC(O)=O.CC(O)=O.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WDRFFJWBUDTUCA-UHFFFAOYSA-N 0.000 description 2
- 239000003082 abrasive agent Substances 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 230000000111 anti-oxidant Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 201000008838 periodontal disease Diseases 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 239000006150 trypticase soy agar Substances 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 239000004246 zinc acetate Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L 7681-57-4 Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229960005164 ACESULFAME Drugs 0.000 description 1
- 229960004998 Acesulfame potassium Drugs 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000609240 Ambelania acida Species 0.000 description 1
- LDDQLRUQCUTJBB-UHFFFAOYSA-N Ammonium fluoride Chemical compound [NH4+].[F-] LDDQLRUQCUTJBB-UHFFFAOYSA-N 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 235000004310 Cinnamomum zeylanicum Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 208000007565 Gingivitis Diseases 0.000 description 1
- 229920001908 Hydrogenated starch hydrolysate Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229960004873 LEVOMENTHOL Drugs 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 240000006217 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 229940041616 Menthol Drugs 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N Methyl salicylate Chemical class COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 229940068977 Polysorbate 20 Drugs 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 229960002799 Stannous Fluoride Drugs 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229940033123 Tannic Acid Drugs 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N Tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L Tin(II) fluoride Chemical group F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- 239000010905 bagasse Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- FXNRKXSSLJKNGH-UHFFFAOYSA-L dipotassium;fluoro-dioxido-oxo-$l^{5}-phosphane Chemical compound [K+].[K+].[O-]P([O-])(F)=O FXNRKXSSLJKNGH-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000005581 enamel erosion Diseases 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 150000008195 galaktosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical class O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000006678 peppermint Nutrition 0.000 description 1
- 235000015132 peppermint Nutrition 0.000 description 1
- 235000007735 peppermint Nutrition 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000003449 preventive Effects 0.000 description 1
- 230000000529 probiotic Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 230000000395 remineralization Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
Abstract
A liquid oral care composition comprising: • a galactooligosaccharide; and • xylitol; for use in the treatment or prophylaxis of an oral bacterial infection.
Description
ANTIBACTERIAL ORAL COMPOSITIONS
This invention relates to a liquid oral care composition comprising a galactooligosaccharide and xylitol which is effective in preventing or reducing symptoms associated with halitosis and cavities.
BACKGROUND OF THE INVENTION
Oral hygiene is an important consideration in the daily life of children and adults around the globe. The maintenance of good oral hygiene is vital to keep the mouth, teeth and gums free from disease, and to prevent the growth of bacteria which can lead to the development of halitosis (bad breath) and also to dental caries (tooth decay).
Bacteria, in particular Fusobactehum nucleatum and Porphyromonas gingivalis, located in periodontal pockets and at the back of the tongue break down sulfur-containing amino acids, in particular cysteine and methionine, to produce the volatile sulfur compounds, including hydrogen sulfide and methyl mercaptan.
These volatile sulfur compounds have an extremely unpleasant odor, even at low concentrations, and also penetrate the epithelium and cause damage to cells of the underlying tissue. It has also been suggested that volatile sulfur compounds produced by bacteria located within periodontal pockets may be an important factor in the development of periodontal disease.
Bacteria, in particular Streptococcus mutans, are also responsible for dental caries (tooth decay or cavities). Streptococcus mutans metabolises sucrose to lactic acid creating an acidic environment in the mouth that can cause tooth enamel to be vulnerable to decay.
Therefore, antibacterial agents are often used in preventive dentistry to reduce the levels of these bacteria and thereby prevent or reduce symptoms associated with halitosis and cavities, and it is an object of the present invention to provide a liquid oral care composition which is effective in preventing or reducing these symptoms.
SUMMARY OF THE INVENTION
In a first aspect, the invention provides a liquid oral care composition comprising:
• a galactooligosaccharide; and
• xylitol; for use in the treatment or prophylaxis of an oral bacterial infection.
In a second aspect, the invention provides an oral care composition comprising:
• a galactooligosaccharide; and
• xylitol;
for use in the treatment or prophylaxis of halitosis or dental caries.
In a third aspect, the invention provides an oral care composition which is a mouthwash, mouthrinse or spray comprising:
• a galactooligosaccharide; and
• xylitol; for use in the treatment or prophylaxis of an oral bacterial infection.
In a fourth aspect, the invention provides an oral care composition which is a mouthwash, mouthrinse or spray comprising:
• a galactooligosaccharide; and
• xylitol; for use in the treatment or prophylaxis of halitosis or dental caries.
Surprisingly, the applicant has found that a formulation comprising galactooligosaccharide and xylitol has a beneficial effect on deleterious bacteria in the mouth and therefore is useful for the treatment or prophylaxis of oral bacterial infections, in particular halitosis and dental caries.
DETAILED DESCRIPTION OF THE INVENTION
The invention provides an oral care composition comprising:
• a galactooligosaccharide; and
• xylitol; for use in the treatment or prophylaxis of (i) an oral bacterial infection or (ii) halitosis or dental caries.
Galactooligosaccharide
The topical formulation includes a galactooligosaccharide. For the avoidance of doubt, the term galactooligosaccharide includes mixtures (i.e. one or more) galactooligosaccharides, and formulations comprising mixtures of galactooligosaccharides are covered by the invention.
Galactooligosaccharides belong to the group of prebiotics, which are non-digestible food ingredients that beneficially affect the host by stimulating the growth and/or the activity of beneficial bacteria. Galactooligosaccharide is present in commercially available products such as food for both infants and adults. Galactooligosaccharides are produced through the enzymatic conversion of lactose or from a botanical source, and its composition of the galactooligosaccharide fraction varies in chain length and type of linkage between the monomer units.
Galactooligosaccharides are oligomers or polymers of galactose molecules ending mainly with a glucose or sometimes ending with a galactose molecule and have varying degrees of polymerization and types of linkages. In one embodiment, galactooligosaccharide comprises galactose and glucose molecules. In another embodiment, galactooligosaccharide comprises only galactose molecules. In a further embodiment, galactooligosaccharide are galactose-containing oligosaccharides of the form of [p-D-Gal-(1 -6)]n-p-D-Gal-(1 -4)-D-Glc wherein n is 2-20. In another embodiment, the galactooligosaccharide are galactose-containing oligosaccharides of the form Glc-a-1 -4-[p-Gal1 -6]n where n=2-20. In another embodiment, the galactooligosaccharides are in the form of a-D-Glc(1 -4)-[p- D-Gal-(1 -6)]n, where n=2-20. Gal is a galactopyranose unit and Glc (or Glu) is a glucopyranose unit.
Galactooligosaccharides are found in human and bovine maternal milk. Galactooligosaccharides can be produced from lactose syrup using the transgalactosylase activity of the enzyme b-galactosidase (Crittenden, (1999) Probiotics: A Critical Review. Tannock, G. (ed) Horizon Scientific Press, Wymondham, pp. 141 -156). b-D-galactosidase is known to catalyze not only the hydrolysis of the b-D- galactoside linkage of lactose to give D-glucose and D-galactose but also to carry out transgalactosylation reactions where the D-galactosyl group of a b-D-galactoside is transferred onto a hydroxylated acceptor. For example, when a b-D-galactoside such as lactose or another carbohydrate is present, it is possible to obtain new glycoside linkages between the D-galactose unit and the acceptor. The starting galactoside such as lactose can also be present in a galactooligosaccharide mixture following the transgalactosylation reactions.
As used herein, galactooligosaccharide comprises one or more saccharides that have been produced from a glycoside and the transgalactosylation reaction of a b-galactosidase. Thus, galactooligosaccharides include saccharides such as transgalactosylated oligosaccharides (i.e. transgalacto-oligosaccharides) or transgalactosylate disaccharides. The degrees of polymerization (DP) of the formed oligosaccharide can vary, typically from 2-20, depending on the enzyme source. In one embodiment, a galactooligosaccharides composition is a blend of one more saccharides with a DP range of 2-6 (i.e. di- through hexasaccharides).
In another embodiment, a galactooligosaccharides composition is a blend of one or more saccharides with a DP range of 2-8 (i.e. di- through octa-saccharides). In another embodiment, a galactooligosaccharide composition is a blend of one or more saccharides with a DP range of greater than 8. In yet another embodiment, a galactooligosaccharides composition is a blend of one or more saccharides with a DP range of 9-15. In another embodiment, a galactooligosaccharides composition is a blend of one or more saccharides with a DP of 1 , a DP range of 2-6, a DP range of 6-8, and DP range of greater than 8.
In one embodiment, the oral care composition comprises 0.01 % to 10% w/w galactooligosaccharide, for example 0.01 % to 5% w/w galactooligosaccharide. Alternatively, the composition comprises 0.1 % to 5% w/w galactooligosaccharide or 0.5% to 5% w/w galactooligosaccharide.
In a preferred embodiment, the oral care composition comprises 0.01 % to 5% w/w galactooligosaccharide.
Xylitol
The oral care composition includes xylitol. Xylitol is a naturally occurring sugar alcohol used as a sweetener. It is found in low concentrations in the fibers of many fruits and vegetables and can be extracted from various berries, oats, and mushrooms, as well as fibrous material such as cornhusks and sugar cane bagasse.
In one embodiment, the oral care composition comprises 0.01 % to 10% w/w, in particular 0.01 % to 5% w/w xylitol. Alternatively, the oral care composition comprises 0.1 % to 5% w/w xylitol or 0.5% to 5% w/w xylitol.
In a preferred embodiment, the oral care composition comprises 0.01 % to 5% w/w xylitol.
In one embodiment, the oral care composition comprises a weight ratio of galactooligosaccharide:xylitol of from 10:1 to 1 :10, from 8:1 to 1 :8, from 5:1 to 1 :5, or from 3:1 to 1 :3.
In a preferred embodiment, the oral care composition comprises a weight ratio of galactooligosaccharide:xylitol of from 2:1 to 1 :2.
Uses of the invention
The applicant has surprisingly discovered that the oral care compositions of the invention have antibacterial effect against and reduce biofilm formation by Fusobactehum nucleatum, Porphyromonas gingivalis and Streptococcus mutans.
Fusobacterium nucleatum and Porphyromonas gingivalis, located in periodontal pockets and at the back of the tongue break down sulfur-containing amino acids, in particular cysteine and methionine, to produce volatile sulfur compounds, including hydrogen sulfide and methyl mercaptan. These volatile sulfur compounds have an extremely unpleasant odor, even at low concentrations, and also penetrate the epithelium and cause damage to cells of the underlying tissue. It has also been suggested that volatile sulfur compounds produced by bacteria located within periodontal pockets may be an important factor in the development of periodontal disease.
Other bacteria, in particular Streptococcus mutans, are responsible for dental caries (tooth decay or cavities). Streptococcus mutans metabolises sucrose to give lactic acid, which creates an acidic environment in the mouth that can cause tooth enamel to be vulnerable to decay.
Accordingly, the oral care compositions are for use in therapy for the treatment or prophylaxis of an oral bacterial infection, halitosis or dental caries, in particular by topical application to the oral cavity i.e. by oral topical application.
In one embodiment, the invention provides a liquid oral care composition comprising:
• a galactooligosaccharide; and
• xylitol; for use in the treatment or prophylaxis of an oral bacterial infection.
In particular, the oral bacterial infection is associated with or caused by Fusobactehum nucleatum or Porphyromonas gingivalis.
In one embodiment, the invention provides a liquid oral care composition comprising:
• a galactooligosaccharide; and
• xylitol; for use in the treatment or prophylaxis of halitosis or dental caries.
In particular, the halitosis or dental caries is associated with or caused by Streptococcus mutans.
In one embodiment, the invention provides a liquid oral care composition comprising:
• a galactooligosaccharide; and
• xylitol; for use in therapy by topical application to the oral cavity, for example for the treatment or prophylaxis of an oral bacterial infection, halitosis or dental caries.
In a further embodiment, the invention provides a liquid oral care composition which is a mouthwash, mouthrinse or a spray, comprising:
• a galactooligosaccharide; and
• xylitol.
In a further aspect, the invention provides a liquid oral care composition comprising a galactooligosaccharide, for example 0.01 % to 10% w/w galactooligosaccharide, 0.01 % to 5% w/w galactooligosaccharide, 0.1 % to 5% w/w galactooligosaccharide or 0.5% to 5% w/w galactooligosaccharide, for use in the treatment or prophylaxis of an oral bacterial infection halitosis or dental caries.
In a further embodiment, the invention provides an oral care composition which is a mouthwash, mouthrinse or a spray, comprising a galactooligosaccharide, for example 0.01 % to 10% w/w galactooligosaccharide, 0.01 % to 5% w/w galactooligosaccharide, 0.1 % to 5% w/w galactooligosaccharide or 0.5% to 5% w/w galactooligosaccharide.
In one embodiment, the invention provides a method for the treatment or prophylaxis of an oral bacterial infection, halitosis or dental caries, comprising the topical application of an effective amount of a liquid oral care composition comprising a galactooligosaccharide and xylitol to the oral cavity of a patient in need thereof.
In another embodiment, the invention provides the use of a galactooligosaccharide and xylitol for the manufacture of a medicament for use in the treatment or prophylaxis an oral bacterial infection, halitosis (i.e. neutralising bad breath) or dental caries.
The invention provides the use of a topical formulation of the invention for preventing the growth of Fusobactehum nucleatum, Porphyromonas gingivalis, and Streptococcus mutans, in particular in the oral cavity of a human or animal.
Again without being bound by theory, it is thought that the topical formulations of the invention prevent the formation of a biofilm of Fusobacterium nucleatum, Porphyromonas gingivalis, and Streptococcus mutans or remove such a biofilm once formed, in the oral cavity of a human or animal.
Accordingly, the invention provides the use of an oral composition of the invention for preventing the formation of a biofilm of Fusobacterium nucleatum, Porphyromonas gingivalis, and Streptococcus mutans or removing such a biofilm once formed, in the oral cavity of a human or animal.
Other uses of the compositions of the invention described herein, in addition to the use forthe treatment of an oral bacterial infection, halitosis or dental caries, are as follows.
The liquid oral care composition comprising a galactooligosaccharide and xylitol as defined herein, including any sub-embodiments thereof, for use in a therapeutic or cosmetic method for:
• cleaning the teeth;
• reducing plaque;
• reducing gingivitis,
• reducing dentinal hypersensitivity;
• removing or preventing stains;
• reducing, inhibiting or repairing dental enamel erosion;
• promoting remineralization of dental enamel; and
• improving the whiteness of the teeth.
The compositions
In one embodiment, the oral care composition is a liquid. In one embodiment, the oral care composition is a mouthwash, mouthrinse or a spray. In particular, the liquid oral care composition is a mouthwash, for example an aqueous mouthwash.
Other components
The oral care composition generally includes water. In addition, the oral care composition includes other additives and adjuvants commonly found in oral care compositions, for example water, fluoride, a masking agent, a humectant, a flavouring agent, an emulsifying agent, and a buffering agent.
Water
Typically, water (i.e. demineralised water) is present as the balance of the composition. In other words, the composition is an aqueous oral care composition.
Fluoride
In one embodiment, the oral care composition includes one or more fluoride salts.
In one embodiment, the fluoride salt is selected from stannous fluoride, sodium fluoride, potassium fluoride, potassium monofluorophosphate, sodium monoflourophosphate, ammonium monoflourophosphate, sodium flourosilicate, ammonium flourosilicate, amine fluorides such ammonium fluoride, and combinations thereof.
In one embodiment, the oral care composition includes an amount of a fluoride salt such that the composition includes from 50 to 5000 ppm, 100 to 1000 ppm fluoride ions, 200 to 500 ppm fluoride ions e.g. about 250 ppm fluoride ions.
In one embodiment, the oral care composition comprises 0.01 to 1 % w/w, 0.01 to 0.1 % w/w, or 0.02 to 0.07% w/w e.g. 0.01 % w/w fluoride salt.
Masking agent
In one embodiment, the oral care composition includes a masking agent, such as tannic acid, glycyrrhizin derivatives, or acesulfame e.g. acesulfame potassium. The masking agent is present in an amount sufficient to reduce the aftertaste of any minerals present in the oral care preparation. In particular, when present, the composition includes 0.01 to 0.1 % w/w masking agent, for example 0.01 to 0.05% w/w masking agent.
Humectant
In one embodiment, the oral care composition includes one or more humectants, such as hydrogenated starch hydrolysate, glycerin, and sorbitol. The humectant is present in an amount sufficient to increase the viscosity and provide a certain mouth feel to the oral care composition. In one embodiment, the composition includes 1 to 10% w/w humectant, for example 5 to 10% w/w e.g. 7.50% w/w of humectant.
Flavouring agent
In one embodiment, the oral care composition includes one or more flavouring agents, such as peppermint, spearmint, cinnamon, wintergreen oils, menthol, or methyl salicylate derivatives. Other flavouring agents may be used individually or in combination. In one embodiment, the composition includes 0.01 to 1 % w/w e.g. 0.2 to 0.5% w/w of a flavouring agent.
Emulsifying agent
In one embodiment, the oral care composition includes one or more emulsifying agents, such as PEG- 40 hydrogenated castor oil, or polysorbate-20. In one embodiment, the composition includes 0.1 to 10% w/w e.g. 1 % w/w of a flavouring agent.
Buffering agent
In another embodiment, the oral care composition includes a buffering agent, such as citric acid, and benzoic acid. In one embodiment, the oral care composition includes a buffering agent in an amount such that the pH of the oral care preparation is from 5 to 8, for example from 5 to 7, and in particular from 5 to 6.
Other components
A variety of additives and adjuvants can be included to make the oral care composition more amenable for use in a particular end-use application without negatively affecting its efficacy or the stability of chlorhexidine in a substantial manner. Examples include, but are not limited to, emollients, fragrances, pigments, dyes, flavors, abrasives, bleaching agents, preservatives, antioxidants, and the like.
Other components
A variety of additives and adjuvants can be included to make the oral care composition more amenable for use in a particular end-use application without negatively affecting its efficacy or the stability of chlorhexidine in a substantial manner. Examples include, but are not limited to, emollients, fragrances, pigments, dyes, flavors, abrasives, bleaching agents, preservatives, antioxidants, and the like.
EXAMPLES
The invention will now be illustrated by reference to the following examples.
Example 1 : Exemplary formulation
An example of a mouthwash according to the invention is as follows (Formulation 1)
It will be appreciated that the above composition is only an example, and the invention is not limited to only such compositions.
The formulations according to the invention are stable, and exhibit good physical and chemical stability over time, even at a temperature above ambient temperature. Example 2: Activity against periodontal and cariogenic pathogens
The aim of the present study is to get information on the in vitro effect of a new mouthwash formulation based on galactooligosaccharide and xylitol against periodontal pathogens (Fusobacterium nucleatum, Porphyromonas gingivalis) and cariogenic pathogens (Streptococcus mutans).
The following formulations were tested: Mouthwash 1
Antibacterial agents: Chlorhexidine diacetate (0.025% w/w)
Other ingredients: Water (77.565 w/w%), zinc acetate (0.3 w/w%), potassium acesulfame (0.03 w/w%), sodium fluoride (0.05 w/w%), hydrogen starch hydrolysate (7.5 w/w%), alcohol (1.2 w/w%), aroma (0.8 w/w%), PEG-40 hydrogenated castor oil (2.4 w/w%), glycerin (10.1 w/w%) and citric acid (0.03 w/w%).
Mouthwash 3
Antibacterial agents: Galactooligosaccharide (2% w/w) and xylitol 2% (w/w)
Other ingredients: Water (74.150 w/w%), zinc acetate (0.3 w/w%), potassium acesulfame (0.03 w/w%), sodium fluoride (0.05 w/w%), hydrogen starch hydrolysate (7.5 w/w%), aroma (0.6 w/w%), PEG-40 hydrogenated castor oil (2.4 w/w%), glycerin (10.1 w/w%), sodium metabisulfite (0.15 w/w%), benzyl alcohol (0.5 w/w%) and citric acid (0.02 w/w%).
Bacterial strains
Fusobactehum nucleatum (ATCC 25586), Porphyromonas gingivalis (ATCC 33277) and Streptococcus mutans (CH 02) reference clinical strain were used. Fusobacterium nucleatum and Porphyromonas gingivalis were cultured overnight in trypticase soy broth (TSB) with hemin and vitamin K at 37°C for 48-72h and Streptococcus mutans was cultured overnight in TSB with 1 % sucrose at 37°C for 24-48h, under anaerobic atmospheres. After incubation, all broth cultures were adjusted to 0.5 McFarland. The strains were stored at -80°C in microbanks.
The effect on planktonic phase: Colony-forming unit (CFU) determination
The CFU determination was performed to evaluate the effect of the compositions on the bacterial planktonic phase (i.e. the single-cells in the liquid medium).
Afterthe contact of the broth cultures with either the formulations (1 :1 v/v) orthe saline solution (control) for a particular time period under anaerobic conditions at 37 °C, serial ten-fold dilutions were performed and were spread on Anaerobe Basal Agar (ABA) with 5% sheep blood for Fusobacterium nucleatum and Porphyromonas gingivalis, and on Tripticase Soy Agar (TSA) with 5% sheep blood for Streptococcus mutans.
After incubation under anaerobic condition at 37°C for 48-72h and for 24-48h respectively, the number of CFU/ml were recorded to detect the bacterial count. Each measurement was be performed in triplicate.
The efficacy of the compositions was measured by determining the % log reduction in CFU/ml and the % reduction in CFU/ml:
%log reduction (CFU/ml) = 100— \ og[CFU /ml]/\og[CFU (control) /ml] ]x 100 % reduction (CFU/ml) = 100— [[ CFU/ml]/[CFU(control)/ml ] ] x 100
The effect on microbial biofilm formation
The efficacy of the compositions on biofilm formation was evaluated by determining biomass production. Standardized bacterial suspensions grown in TSB with hemin and vitamin K (for Fusobacterium
nucleatum and Porphyromonas gingivalis) and with 1 % sucrose (for Streptococcus mutans) were incubated on 96-wells flat-bottomed microtiter plates at 37°C for 48-72h under anaerobic conditions.
After incubation, each well was washed twice with sterile PBS (pH 7.4), dried, stained for 1 min with 0.1 % crystal violet, and eluted with ethanol. The biomass was measured by spectrophotometer using an enzyme-linked-immune adsorbent assay (ELISA) reader OD570. Each measurement was performed in triplicate.
Statistical analysis
The significance of the results relative to the controls was evaluated using Student’s t-test.
Periodontal pathogens The amount of bacteria was measured in terms of Colony-Forming Unit i.e. CFU/ml after treatment with formulations 1 and 3, and the amount of biofilm reduction was determined relative to the control.
All data show statistical significance i.e p<0.01 reductions.
Porphyromonas gingivalis
Cariogenic pathogens The amount of bacteria was measured in terms of Colony-Forming Unit i.e. CFU/ml after treatment with formulations 1 and 3, and the amount of biofilm reduction was determined relative to the control.
All data show statistical significance i.e p<0.01 reductions.
Streptococcus mutans
The amount of bacteria was measured in terms of Colony-Forming Unit i.e. CFU/ml after treatment with formulations 1 and 3, and the amount of biofilm reduction was determined relative to the control.
Discussion
The mouthwash comprising galactooligosaccharide and xylitol provides a comparable action against to that obtained with the leading composition comprising chlorhexidine diacetate and zinc zcetate on periodontal and cariogenic pathogens and against planktonic and sessile phases.
Claims
1 . A liquid oral care composition comprising:
• a galactooligosaccharide; and
• xylitol; for use in the treatment or prophylaxis of an oral bacterial infection.
2. A liquid oral care composition comprising:
• a galactooligosaccharide; and
• xylitol; for use in the treatment or prophylaxis of halitosis or dental caries.
3. The liquid oral care composition for use as claimed in claim 1 or 2, wherein the formulation comprises 0.01 % to 10% w/w xylitol.
4. The liquid oral care composition for use as claimed in any one of claims 1 to 3, wherein the formulation comprises 0.01 % to 5% w/w xylitol.
5. The liquid oral care composition for use as claimed in any one of claims 1 to 4, wherein the formulation comprises 0.01 % to 10% w/w galactooligosaccharide.
6. The liquid oral care composition for use as claimed in any one of claims 1 to 5, wherein the formulation comprises 0.01 % to 5% w/w galactooligosaccharide.
7. The liquid oral care composition for use as claimed in any one of claims 1 to 6, wherein the formulation comprises a weight ratio of galactooligosaccharide:xylitol of from 10:1 to 1 :10.
8. The liquid oral care composition for use as claimed in any one of claims 1 to 7 wherein the formulation comprises a weight ratio of galactooligosaccharide:xylitol of from 2:1 to 1 :2.
9. The liquid oral care composition for use as claimed in any one of claims 1 to 8, wherein the composition is mouthwash, mouthrinse or a spray.
10. The oral care composition for use as claimed in any one of claims 1 to 9, wherein the formulation is an aqueous mouthwash.
1 1 . A liquid oral care composition comprising:
• a galactooligosaccharide; and
• xylitol; for use in therapy by topical application to the oral cavity.
12. The liquid oral care composition for use as claimed in any one of claims 9 to 1 1 , wherein the formulation is for the treatment or prophylaxis of an oral bacterial infection, halitosis or dental caries.
13. The liquid oral care composition for use as claimed in claim 12, wherein the oral bacterial infection, halitosis or dental caries is associated with Fusobactehum nucleatum, Porphyromonas gingiva!is, or Streptococcus mutans.
14. The use of a liquid oral care composition as defined in any one of claims 1 to 10 as a cosmetic.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20701531.4A EP3906011A1 (en) | 2019-01-02 | 2020-01-02 | Antibacterial oral compositions |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1900031.4 | 2019-01-02 | ||
| GBGB1900031.4A GB201900031D0 (en) | 2019-01-02 | 2019-01-02 | Antibacterial oral compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2020141201A1 true WO2020141201A1 (en) | 2020-07-09 |
Family
ID=65364720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2020/050044 WO2020141201A1 (en) | 2019-01-02 | 2020-01-02 | Antibacterial oral compositions |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3906011A1 (en) |
| GB (1) | GB201900031D0 (en) |
| WO (1) | WO2020141201A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009114125A (en) * | 2007-11-06 | 2009-05-28 | Nippon Zettoc Co Ltd | Oral composition |
| US20120237457A1 (en) * | 2011-03-20 | 2012-09-20 | Chen Shu-Cheng | Anti-bacterial oral care composition and method for producing the same |
| CN106234745A (en) * | 2016-08-10 | 2016-12-21 | 袁春华 | A kind of preparation method of child edible mouth care sugar-tablet |
| WO2019002421A1 (en) * | 2017-06-27 | 2019-01-03 | Rottapharm Spa | Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments |
-
2019
- 2019-01-02 GB GBGB1900031.4A patent/GB201900031D0/en not_active Ceased
-
2020
- 2020-01-02 EP EP20701531.4A patent/EP3906011A1/en active Pending
- 2020-01-02 WO PCT/EP2020/050044 patent/WO2020141201A1/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009114125A (en) * | 2007-11-06 | 2009-05-28 | Nippon Zettoc Co Ltd | Oral composition |
| US20120237457A1 (en) * | 2011-03-20 | 2012-09-20 | Chen Shu-Cheng | Anti-bacterial oral care composition and method for producing the same |
| CN106234745A (en) * | 2016-08-10 | 2016-12-21 | 袁春华 | A kind of preparation method of child edible mouth care sugar-tablet |
| WO2019002421A1 (en) * | 2017-06-27 | 2019-01-03 | Rottapharm Spa | Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments |
Non-Patent Citations (3)
| Title |
|---|
| CRITTENDEN: "Probiotics: A Critical Review", 1999, HORIZON SCIENTIFIC PRESS, pages: 141 - 156 |
| DATABASE WPI Week 200937, Derwent World Patents Index; AN 2009-J69226, XP002797828 * |
| DATABASE WPI Week 201718, Derwent World Patents Index; AN 2017-03519V, XP002797827 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3906011A1 (en) | 2021-11-10 |
| GB201900031D0 (en) | 2019-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10765616B2 (en) | Oral formulation of polyglucosamine derivatives in combination with a non-fermentable sugar | |
| US10328010B2 (en) | Prebiotic oral care methods using a saccharide | |
| CA2431044A1 (en) | Oral compositions and use thereof | |
| US20070098650A1 (en) | Dental formulation | |
| TWI733123B (en) | Prebiotic oral care compositions containing an alkyl glycoside | |
| Marya et al. | Efficacy of Chlorhexidine, Xylitol, and Chlorhexidine+ Xylitol against Dental Plaque, Gingivitis, and Salivary Streptococcus mutans Load: A Randomised Controlled Trial. | |
| EP4044996A1 (en) | Oral care composition | |
| JP2001247469A (en) | Medicine for dental caries and periodontal disease, and composition which contain the medicine and is used for oral cavity, and drink or food containing the medicine | |
| WO2020141201A1 (en) | Antibacterial oral compositions | |
| RU2789083C2 (en) | Method for obtaining a dextranase preparation and its use | |
| RU2741492C2 (en) | Methods of oral care with using saccharide as a prebiotic | |
| Ravichandran et al. | Comparative evaluation of the efficacy of xylitol toothpaste and xylitol chewing gum on salivary parameters: An in-vivo study. | |
| KR20230040578A (en) | Composition for Inhibiting Biofilm Formation and for Preventing or Treating Dental Disease | |
| US20220226232A1 (en) | Dental formulation comprising xylitol and propolis | |
| EP3808327A1 (en) | Oral care compositon | |
| DE10065413A1 (en) | Dentifrice | |
| WO2022072669A1 (en) | Prebiotic oral care compositions and methods | |
| KR20170120408A (en) | Composition for prevention or treatment of oral disease comprising Qucercetin 3-glucoside | |
| KR20110074223A (en) | Composition for preventing and improving periodontal disease | |
| KR20170120404A (en) | Composition for prevention or treatment of oral disease comprising 2-methoxycinnamaldehyde | |
| KR20170120414A (en) | Composition for prevention or treatment of oral disease comprising Esculetin | |
| KR20170120399A (en) | Composition for prevention or treatment of oral disease comprising Genistein | |
| KR20170120416A (en) | Composition for prevention or treatment of oral disease comprising Matairesinol | |
| KR20170120411A (en) | Composition for prevention or treatment of oral disease comprising Scopoletin | |
| KR20170120405A (en) | Composition for prevention or treatment of oral disease comprising Arctiin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20701531 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2020701531 Country of ref document: EP Effective date: 20210802 |